etoposide has been researched along with epidermal growth factor in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Hamburger, AW; Mishra, S | 1 |
| Ahn, DC; Doroshow, JH; Forman, SJ; Hwang, L; Leong, LA; Lev-Ran, A; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G | 1 |
| Furukawa, S; Hayashi, K; Hayashi, Y; Kashiwagi, K; Kawashima, T; Nakajima, M; Ohta, J | 1 |
| Adams, GE; Jones, AM; Kalra, R; Kirk, J; Stratford, IJ | 1 |
| Allen, GC; Devore, RF; Lubas, S; Wax, MK | 1 |
| Beinert, T; Binder, D; Fleischhacker, M; Mergenthaler, HG; Oehm, C; Possinger, K; Priem, F; Schweigert, M; Sezer, O; Siebert, G; Stuschke, M; Werner, TG; Ziemer, S | 1 |
| Freeman, MR; Gaston, SM; Hutchinson, L; Lin, J; Raab, G | 1 |
| Colvin, OM; Harris, LN; Hsieh, TS; Iglehart, JD; Liotcheva, V; Pauli, S; Yang, L | 1 |
| Anderson, SM; Barzen, KA; Limesand, KH; Quissell, DO | 1 |
| Dalrymple, C; Lee, V; Parker, A; Russell, P; Valmadre, S | 1 |
| Bor, MV; Nexø, E; Sørensen, BS; Tørring, N | 1 |
| Brown, JG; Gibson, SB; Graham, BA; Harding, G; Hu, X; Paul, JT; Shetty, S; Vegh-Yarema, N | 1 |
| Nexo, E; Ornskov, D; Sorensen, BS | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| O'Grady, P; Saito, H; Takekawa, M; Tomida, T | 1 |
| Guo, Y; Jiang, X; Li, Z; Wang, G; Xi, Z; Yan, B; Yao, Y | 1 |
| Chen, C; Ji, XM; Liu, YQ; Tao, Q; Wang, QL; Xie, XX; Yu, SQ; Zhang, FY; Zhou, Q; Zou, Y | 1 |
| Bouzekri, A; Esch, A; Ornatsky, O | 1 |
| Bal, A; Gupta, N; Gupta, P; Khosla, D; Shastri, M; Singh, N; Srinivasan, R | 1 |
1 trial(s) available for etoposide and epidermal growth factor
| Article | Year |
|---|---|
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Creatinine; Cyclophosphamide; Dopamine; Double-Blind Method; Electrolytes; Epidermal Growth Factor; Etoposide; Female; Hearing Loss; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Sarcoma; Soft Tissue Neoplasms; Water-Electrolyte Imbalance | 1995 |
18 other study(ies) available for etoposide and epidermal growth factor
| Article | Year |
|---|---|
O-phospho-L-tyrosine inhibits cellular growth by activating protein tyrosine phosphatases.
Topics: Breast Neoplasms; Carcinoma, Renal Cell; Cell Death; Cell Division; Doxorubicin; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Etoposide; Humans; Kidney Neoplasms; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatases; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Tyrosine | 1993 |
Nerve growth factor and epidermal growth factor rescue PC12 cells from programmed cell death induced by etoposide: distinct modes of protection against cell death by growth factors and a protein-synthesis inhibitor.
Topics: Animals; Apoptosis; Cell Survival; Culture Media; DNA; Epidermal Growth Factor; Etoposide; L-Lactate Dehydrogenase; Nerve Growth Factors; PC12 Cells; Protein Synthesis Inhibitors; Rats; RNA, Messenger; Topoisomerase II Inhibitors | 1994 |
The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells in vitro.
Topics: Animals; Breast Neoplasms; Cell Hypoxia; Cricetinae; Cricetulus; Doxorubicin; Drug Resistance; Epidermal Growth Factor; Etoposide; Fibroblasts; Humans; Lung; Tumor Cells, Cultured | 1993 |
Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Squamous Cell; Catalysis; Cell Division; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Etoposide; Head and Neck Neoplasms; Humans; KB Cells; Tumor Cells, Cultured | 1996 |
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Albumins; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphokines; Male; Middle Aged; Neoplasm Proteins; Neovascularization, Pathologic; Oxidative Stress; Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vindesine | 1999 |
BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation.
Topics: Animals; Apoptosis; Binding Sites; Carrier Proteins; Cell Adhesion; Cell Division; Cell Membrane; Cell Survival; CHO Cells; COS Cells; Cricetinae; Cytoplasm; DNA-Binding Proteins; Dose-Response Relationship, Drug; Epidermal Growth Factor; Etoposide; Glutathione Transferase; Heparin; HSP70 Heat-Shock Proteins; Humans; Microscopy, Confocal; Nucleic Acid Synthesis Inhibitors; Protein Binding; Protein Isoforms; Protein Structure, Tertiary; Recombinant Fusion Proteins; Time Factors; Transcription Factors; Transfection; Tumor Cells, Cultured; Two-Hybrid System Techniques; Ubiquitins | 2001 |
Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Nucleus; Cyclophosphamide; DNA; DNA Topoisomerases, Type II; Doxorubicin; Enzyme Activation; Epidermal Growth Factor; Etoposide; Female; Humans; Mice; Nucleic Acid Synthesis Inhibitors; Protein Binding; Receptor, ErbB-2; Signal Transduction; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
Synergistic suppression of apoptosis in salivary acinar cells by IGF1 and EGF.
Topics: Adenoviridae; Animals; Apoptosis; Cells, Cultured; DNA Fragmentation; Dose-Response Relationship, Drug; Epidermal Growth Factor; Etoposide; Growth Substances; Humans; Immunoblotting; Insulin-Like Growth Factor I; Mice; Phosphatidylinositol 3-Kinases; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Salivary Glands; Time Factors | 2003 |
Epithelioid trophoblastic tumour: report of a case in the fallopian tube.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Dactinomycin; Disease-Free Survival; Doxorubicin; Epidermal Growth Factor; Epithelioid Cells; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Hysterectomy; Immunohistochemistry; Inhibins; Leucovorin; Methotrexate; Pregnancy; Treatment Outcome; Trophoblastic Neoplasms; Uterine Neoplasms; Vincristine | 2003 |
The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced.
Topics: Amphiregulin; Antineoplastic Agents, Phytogenic; Betacellulin; Cell Line, Tumor; Cell Membrane; Cycloheximide; Dose-Response Relationship, Drug; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Etoposide; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Ligands; Protein Synthesis Inhibitors; RNA, Messenger; Transforming Growth Factor alpha; Urinary Bladder Neoplasms | 2004 |
Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.
Topics: Apoptosis; Binding Sites; Breast Neoplasms; Cell Culture Techniques; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Epidermal Growth Factor; Etoposide; Female; Gene Expression Regulation; Genes, Reporter; Histone Deacetylases; Humans; Introns; Kidney; Luciferases; Mutation; NF-kappa B; Nucleic Acid Synthesis Inhibitors; Protein Binding; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Time Factors; Tumor Suppressor Protein p53 | 2005 |
The chemotherapeutic agent VP16 increases the stability of HB-EGF mRNA by a mechanism involving the 3'-UTR.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Epidermal Growth Factor; ErbB Receptors; Etoposide; Gene Expression Regulation; HeLa Cells; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Peptides; Promoter Regions, Genetic; Receptor, ErbB-4; RNA Stability; RNA, Messenger; Transcription, Genetic | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Stimulus-specific distinctions in spatial and temporal dynamics of stress-activated protein kinase kinase kinases revealed by a fluorescence resonance energy transfer biosensor.
Topics: Animals; Biosensing Techniques; Cell Membrane; Cell Nucleus; Cell Survival; Chlorocebus aethiops; COS Cells; Enzyme Activation; Epidermal Growth Factor; Etoposide; Fluorescence Resonance Energy Transfer; Genes, Reporter; HeLa Cells; Humans; MAP Kinase Kinase Kinases; Mutation; Subcellular Fractions; Time Factors; Ultraviolet Rays | 2009 |
Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Etoposide; Gefitinib; Green Fluorescent Proteins; Humans; Immunoblotting; Microscopy, Immunoelectron; Mitochondria; Mitochondrial Proteins; Mutation; Protein Transport; Quinazolines | 2010 |
EGF-functionalized single-walled carbon nanotubes for targeting delivery of etoposide.
Topics: Antineoplastic Agents; Binding, Competitive; Cell Death; Cell Line, Tumor; Drug Delivery Systems; Epidermal Growth Factor; Etoposide; Humans; Nanotubes, Carbon; Spectrophotometry, Ultraviolet; Spectrum Analysis, Raman; Thermodynamics | 2012 |
Multidimensional profiling of drug-treated cells by Imaging Mass Cytometry.
Topics: Biomarkers, Tumor; Cell Proliferation; Epidermal Growth Factor; Etoposide; Humans; Image Cytometry; MCF-7 Cells; Microscopy, Fluorescence; Nocodazole; Phenotype; Software; Tumor Cells, Cultured | 2019 |
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carboplatin; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |